Stock HEAL PT MEDIKALOKA HERMINA TBK
Add to a list
To use this feature you must be a member
Log inSign up

Financials PT Medikaloka Hermina Tbk

Equities

HEAL

ID1000143100

Healthcare Facilities & Services

End-of-day quote INDONESIA S.E.
Other stock markets
 18:00:00 2024-07-04 EDT 		5-day change 1st Jan Change
1,340 IDR +3.08% Intraday chart for PT Medikaloka Hermina Tbk -2.55% -10.07%
04-26 PT Medikaloka Hermina Tbk Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
03-28 PT Medikaloka Hermina Tbk Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 10,643,340 10,459,390 15,701,180 22,417,924 21,692,778 19,952,640 - -
Enterprise Value (EV) 2 11,345 11,152 16,078 23,380 23,098 21,479 20,877 21,796
P/E ratio 42.3 x 22.6 x 15.9 x 75.4 x 50.1 x 32.6 x 27.7 x 22 x
Yield - 0.71% 0.56% 0.57% - 0.59% 0.92% 1.19%
Capitalization / Revenue 2.93 x 2.37 x 2.7 x 4.57 x 3.75 x 2.97 x 2.69 x 2.32 x
EV / Revenue 3.12 x 2.53 x 2.76 x 4.77 x 3.99 x 3.2 x 2.81 x 2.53 x
EV / EBITDA 13.1 x 8.04 x 7.26 x 20.5 x 15.8 x 11.3 x 9.74 x 8.71 x
EV / FCF -3,374 x 23.9 x 25 x -89.5 x -85 x -122 x 82.6 x 52.5 x
FCF Yield -0.03% 4.19% 4% -1.12% -1.18% -0.82% 1.21% 1.91%
Price to Book 4.96 x 4.09 x 4.87 x 6.52 x 5.61 x 4.48 x 4 x 3.6 x
Nbr of stocks (in thousands) 14,865,000 14,815,000 14,674,000 14,463,176 14,558,911 14,890,030 - -
Reference price 3 716.0 706.0 1,070 1,550 1,490 1,340 1,340 1,340
Announcement Date 20-04-05 21-05-17 22-03-31 23-03-31 24-03-28 - - -
1IDR in Million2IDR in Billions3IDR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 3,631 4,416 5,820 4,902 5,784 6,710 7,427 8,604
EBITDA 1 866.6 1,387 2,213 1,142 1,464 1,893 2,143 2,502
EBIT 1 583.3 1,042 1,778 587.4 818 1,058 1,256 1,478
Operating Margin 16.06% 23.59% 30.55% 11.98% 14.14% 15.77% 16.91% 17.18%
Earnings before Tax (EBT) 1 505.5 946 1,658 480.1 710.4 966.3 1,148 1,444
Net income 1 255.4 473.2 1,003 298.6 437.3 605.5 715.1 893.2
Net margin 7.03% 10.72% 17.24% 6.09% 7.56% 9.02% 9.63% 10.38%
EPS 2 16.92 31.18 67.28 20.57 29.73 41.12 48.42 60.77
Free Cash Flow 3 -3,362 466,723 642,792 -261,272 -271,707 -176,342 252,830 415,249
FCF margin -92.59% 10,568.81% 11,044.3% -5,330.11% -4,697.49% -2,627.89% 3,404.26% 4,826.12%
FCF Conversion (EBITDA) - 33,649.82% 29,040.59% - - - 11,796.17% 16,594.34%
FCF Conversion (Net income) - 98,626.65% 64,078.89% - - - 35,354.14% 46,490.47%
Dividend per Share 2 - 5.000 6.000 8.874 - 7.945 12.39 15.92
Announcement Date 20-04-05 21-05-17 22-03-31 23-03-31 24-03-28 - - -
1IDR in Billions2IDR3IDR in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2023 Q1 2023 Q3 2023 Q4
Net sales 1 1,193 - 1,538 1,554
EBITDA 469.1 - - -
EBIT 1 358.7 - - 178.6
Operating Margin 30.07% - - 11.49%
Earnings before Tax (EBT) 1 327.7 - - 150.2
Net income 1 230 108.9 - 88.51
Net margin 19.28% - - 5.69%
EPS - 7.490 - -
Dividend per Share - - - -
Announcement Date 22-03-31 23-04-25 23-10-18 24-03-28
1IDR in Billions
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 701 692 376 962 1,405 1,526 924 1,843
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 0.8094 x 0.4992 x 0.17 x 0.8426 x 0.9599 x 0.8061 x 0.4313 x 0.7366 x
Free Cash Flow 2 -3,362 466,723 642,792 -261,272 -271,707 -176,342 252,830 415,249
ROE (net income / shareholders' equity) 12.7% 20.1% 34.5% 8.1% 12% 14.1% 15.4% 16.7%
ROA (Net income/ Total Assets) 5.54% 8.3% 14.4% 5% 5.34% 7.54% 7.99% 9.21%
Assets 1 4,610 5,702 6,971 5,972 8,197 8,029 8,949 9,700
Book Value Per Share 3 144.0 172.0 220.0 238.0 266.0 299.0 335.0 372.0
Cash Flow per Share 3 37.90 74.20 125.0 59.80 89.70 100.0 110.0 123.0
Capex 1 576 890 1,214 1,129 1,591 1,758 1,294 1,543
Capex / Sales 15.86% 20.15% 20.85% 23.03% 27.51% 26.2% 17.42% 17.93%
Announcement Date 20-04-05 21-05-17 22-03-31 23-03-31 24-03-28 - - -
1IDR in Billions2IDR in Million3IDR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for PT Medikaloka Hermina Tbk

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
1,340 IDR
Average target price
1,688 IDR
Spread / Average Target
+25.93%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

1st Jan change Capi.
PT MEDIKALOKA HERMINA TBK Stock PT Medikaloka Hermina Tbk
-10.07% 1.19B
HCA HEALTHCARE, INC. Stock HCA Healthcare, Inc.
+18.33% 85.53B
CVS HEALTH CORPORATION Stock CVS Health Corporation
-28.29% 71.18B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY Stock Dr. Sulaiman Al Habib Medical Services Group Company
+0.99% 26.76B
FRESENIUS SE & CO. KGAA Stock Fresenius SE & Co. KGaA
+3.67% 17.43B
LABCORP HOLDINGS INC. Stock Labcorp Holdings Inc.
-9.99% 17.18B
QUEST DIAGNOSTICS INCORPORATED Stock Quest Diagnostics Incorporated
+1.86% 15.65B
NATERA, INC. Stock Natera, Inc.
+79.98% 13.71B
TENET HEALTHCARE CORPORATION Stock Tenet Healthcare Corporation
+74.41% 13.27B
PURE HEALTH HOLDING Stock Pure Health Holding
-25.09% 13.1B
Other Healthcare Facilities & Services
  1. Stock Market
  2. Equities
  3. HEAL Stock
  4. Financials PT Medikaloka Hermina Tbk